Stem-cell treatments prolong OS for blast-phase/accelerated-phase myeloproliferative neoplasms
Click Here to Manage Email Alerts
SAN DIEGO — Patients with Philadelphia chromosome-negative accelerated- or blast-phase myeloproliferative neoplasms who received allogeneic hematopoietic stem cells had a longer median OS than those who did not, according to a study.
The data presented at ASH Annual Meeting “underscores the need for novel management strategies even in (patients) eligible for allo-HCT,” according to a research team led by Anand Ashwin Patel, MD, medical director of the inpatient leukemia service at UChicago Medicine.
Previous research into patients with blast-phase myeloproliferative neoplasms (MPN-BP) found that allogeneic hematopoietic stem-cell treatments are the only current curative option for the condition, although the treatment still carries a low median OS of only about 1 year — above the overall median OS of 0.73 years of patients with blast-phase/accelerated-phase myeloproliferative neoplasms (MPN-BP/AP) treated since 2017, in what Patel characterized as the “current era” of myeloid therapies.
Looking to further examine the effect of the stem-cell therapy on patients with MPN-BP/AP, Patel’s team performed a retrospective chart review across eight institutions for patients with Philadelphia-negative MPN-BP/AP diagnosed since 2017.
The full cohort contained 180 patients, 58 of whom received allogeneic hematopoietic stem-cell treatments. Of the remainder, over 80% were primarily treated with hydroxyurea or JAK inhibitors.
Although overall the 180 patients had a median OS of just 0.72 years from MPN-BP/AP diagnosis, in line with earlier data, the 58 patients who underwent allogeneic hematopoietic stem-cell treatments had a median OS of 1.82 years, with even higher survival rates in patients who received hypomethylating agents as their first-line treatment.
Reference:
Patel A, et al. Outcomes of patients with accelerated/blast-phase MPNs that received allogeneic stem-cell transplant in the current era of myeloid therapies. Presented at: ASH Annual Meeting and Exposition; Dec. 9-12, 2023; San Diego.
Collapse
Meeting News
Click Here to Manage Email Alerts